News

Biognosys secures $5 Million in C round

Bio-Technopark based startup Biognosys offering proteomics solutions has raised $5 million from new and existing investors in an extended series C round. The funds will be used to bring proteomics to the broader life science research market. Biognosys is a proteomics company offering innovative services and products for highly multiplexed protein...

read more

Zurich holds all the biotechnology aces

Zurich – The greater Zurich region has all the aces needed for a successful biotechnology centre, says Roger Nitsch, president of the Schlieren-based company Neurimmune. It has the best and the brightest – and the right infrastructure in the shape of the Bio-Technopark Schlieren-Zurich. The greater Zurich region is well on...

read more

Virometix Closes Financing Round

Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector. Virometix plans to use the new...

read more